According to the American College of Cardiology, nearly 6.7 million Americans have heart failure, more than half with preserved ejection fraction. This condition often leads to frequent ...

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

The findings of this study support the routine use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve kidney outcomes ...

This article was reviewed by Darragh O’Carroll, MD. Diabetes Medications for Weight Loss: What to Know Key takeaways: Some ...

Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ...

PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...

Researchers compared the incidence of infection-related outcomes and hypoglycemia across antidiabetic drug classes in patients with inflammatory arthritis and diabetes.

FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted ...

Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 ...

GLP-1RA use, compared with basal insulin and DPP-4i use, was associated with lower risks for IBD and hospitalization in type 2 diabetes.

In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral ...